- India as a global pricing anchor As seen in APIs and vaccines, India could once again reset global reference pricing for obesity and diabetes drugs -Margin compression vs volume expansion The value pool is shiftingfrom per-unit profitability to patient scale Competitive differentiation evolves -Future moats will likely depend on: Clinical outcomes & next-gen formulations Delivery innovation (oral GLP-1, long-acting injectables) Integrated care ecosystems
Final Takeaway On GLP-1 medications, weight loss is gradual and builds over time
Having a structured program with regular check-ins with your healthcare provider can help ensure youre moving in the right direction and allows for adjustments along the way
Specially formulated with Saffron, a serotonin modulator, that can help support appetite suppression while helping reduce stress
Tom Gavin Fact-Checker Tom Gavin joined Everyday Health as copy chief in 2022 after a lengthy stint as a freelance copy editor
For BPC-157 specifically, intranasal data remains limited